Building on Standards, Achieving Long-Term Success Through Collaboration—A New Chapter in the Diagnosis and Treatment of Peritoneal Tumors Begins

Building on Standards, Achieving Long-Term Success Through Collaboration—A New Chapter in the Diagnosis and Treatment of Peritoneal Tumors Begins

The Clinical Medical College of Tsinghua University held the inauguration ceremony for the Peritoneal Cancer Prevention and Treatment Research Center and the launch meeting for clinical diagnostic and therapeutic technical standards for pseudomyxoma peritonei.

On July 2, 2026, the Inauguration Ceremony of the Peritoneal Cancer Prevention and Treatment Research Center of the Clinical Medical College of Tsinghua University, the Appointment Ceremony for International Experts in Peritoneal Tumors, and the Launch Meeting of Clinical Diagnosis and Treatment Standards for Pseudomyxoma Peritonei were held at Peking Union Medical College Hospital—Tsinghua University. Experts and scholars from both China and abroad attended the event, engaging in in-depth discussions on collaborative innovation in peritoneal cancer prevention and treatment, standardized diagnosis and management of pseudomyxoma peritonei, and the development of group standards. 
 

Professor Dong Jiahong, an academician of the Chinese Academy of Engineering, Dean of the Clinical Medical College of Tsinghua University, and President of Peking Union Medical College Hospital—Tsinghua Changgeng, attended the event and delivered a speech. Academician Dong Jiahong noted that the diagnosis and treatment of peritoneal cancer pose significant clinical challenges. He emphasized that the establishment of the Peritoneal Cancer Prevention and Treatment Research Center will help further integrate multidisciplinary resources and foster deep collaboration between basic research and clinical translation. Moreover, the participation of numerous international and domestic experts will enhance the center’s academic standing and promote the continued deepening of high‑level cooperation in China’s peritoneal cancer prevention and treatment field.

During the event, the academic backgrounds and professional influence of the appointed international experts drew widespread attention. Among them, Professor Ignace De Hingh of the Netherlands focuses primarily on multidisciplinary comprehensive treatment for peritoneal metastatic cancer, CRS plus HIPEC, and pancreatic cancer, with notable scholarly contributions to the standardized diagnosis and treatment of peritoneal tumors and to international collaborative research. Professor Yutaka Yonemura of Japan has long been engaged in research on gastric cancer, malignant tumors of the peritoneal surface, and the comprehensive management of peritoneal metastases, wielding significant international influence in the field of peritoneal cancer therapy.

Academician Dong Jiahong stated that the launch of clinical practice guidelines for pseudomyxoma peritonei marks a new phase in standardizing and normalizing related diagnostic and therapeutic efforts. The development of these standards is a systematic undertaking that requires broad consensus across multiple disciplines, aligning with international cutting-edge practices while remaining grounded in China’s clinical realities, thereby establishing scientifically sound, practical, and effective technical standards to support the enhancement of treatment uniformity and the improvement of patient outcomes.

Figure 1: Academician Dong Jiahong, Dean of the Clinical Medical College at Tsinghua University (left), presents Professor Ignace De Hingh of the Netherlands (right) with the appointment letter for Distinguished Visiting Professor at Tsinghua University. 
 

Professor Xing Jinliang, Honorary Chair of the Tumor Markers Professional Committee and Chair of the Integrative Oncology Branch of the Chinese Anti-Cancer Association, congratulated the launch of the group standard in his address and extended his sincere gratitude to Professor Li Yan, the lead author, all contributing experts, and the participating supporting organizations. He stated that the Integrative Oncology Branch of the Chinese Anti-Cancer Association has consistently upheld the principles of “integrative medicine,” continuously advancing the standardization, precision, and internationalization of cancer diagnosis and treatment. In light of the current situation—where the diagnostic and therapeutic pathways for pseudomyxoma peritonei are complex, key techniques such as CRS plus HIPEC are widely employed, yet a unified national guideline remains lacking—this group standard will provide comprehensive coverage across the entire care continuum, including diagnosis, curative treatment, hyperthermic intraperitoneal chemotherapy, perioperative management, and long-term follow-up. It combines clinical practicality with industry‑wide guidance, playing a vital role in filling the existing standards gap and elevating the level of standardized care in this field.

Figure 2: Professor Xing Jinliang, Honorary Chair of the Tumor Markers Professional Committee and Chair of the Integrative Oncology Branch of the Chinese Anti-Cancer Association, delivers an online address. 
 

At the meeting, Professor Wang Hui from the Sixth Affiliated Hospital of Sun Yat-sen University delivered a welcoming address and officially launched the event. Subsequently, Professor Tang Hongsheng from the First Affiliated Hospital of Guangzhou University of Chinese Medicine chaired the opening of the conference agenda. Professors Peng Zheng from the First Medical Center of the PLA General Hospital, An Songlin from Beijing Century Tan Hospital affiliated with Capital Medical University, and Ma Ruiqing from the team led by Professor Xu Hongbin at the Aerospace Center Hospital each presented an overview of the group standard “Clinical Diagnostic and Treatment Technical Standards for Pseudomyxoma Peritonei,” including its basic framework, drafting plan and requirements, and task allocation. The report emphasized that this standard is the first in China to be jointly developed by leading experts in peritoneal oncology, covering the entire clinical pathway—from diagnosis to follow-up—for pseudomyxoma peritonei. Its aim is to standardize terminology, streamline procedures, enhance treatment outcomes, and improve access to high-quality medical resources.

The report systematically reviews the background behind the development of the standard. At present, pseudomyxoma peritonei remains a rare condition with limited public awareness; its pathological grading system is relatively complex, and the core techniques—such as cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy—are associated with high technical barriers. Moreover, variations persist across institutions in diagnostic evaluation, perioperative management, and follow-up protocols. The experts attending the meeting agreed that it is imperative to expedite the establishment of unified, scientifically sound, and widely applicable technical standards.

According to the introduction, the group standard will be developed around 11 core chapters, covering three major sections—basic specifications, core technologies, and comprehensive management—and will focus on topics such as terminology definitions, scope of application, diagnosis and assessment, key technologies for CRS plus HIPEC, perioperative care, prevention and management of complications, adjuvant therapies, and follow-up management. During the drafting process, the GRADE evidence‑grading system and a modified Delphi method will be uniformly employed to formulate recommendations, ensuring that the standard‑development process is scientifically rigorous, standardized, and well‑organized.

In terms of organization and implementation, the project will leverage relevant professional organizations and multidisciplinary expert teams to establish a robust mechanism for guidance, coordination, drafting, and methodological support, thereby advancing, as planned, the preparation of the draft, expert review, public consultation, and final approval and publication. Following the standard’s release, it will further contribute to the national harmonization of clinical pathways, the capacity-building of regional centers, the refinement of standardized training systems, and the conduct of multi-center real-world studies.

The experts attending the meeting stated that the establishment of the research center and the launch of the group standard are mutually reinforcing: they have not only created a vital platform for collaborative innovation in the prevention and treatment of peritoneal cancer, but also injected new momentum into standardized diagnosis and treatment, discipline development, and talent cultivation in this field. Looking ahead, all stakeholders will continue to deepen both international and domestic cooperation, advance breakthroughs in key technologies and translate research findings into practical applications, thereby continuously enhancing the capacity and quality of peritoneal tumor diagnosis and treatment.

Figure 3: The scene of the inauguration ceremony for the Peritoneal Cancer Prevention and Treatment Research Center of the Clinical Medical College of Tsinghua University, the appointment ceremony for international experts in peritoneal tumors, and the launch meeting for the clinical diagnosis and treatment standards for pseudomyxoma peritonei (with some experts participating online). 
 

The convening of this conference marks a significant step forward in the organizational, platform‑based, and standardized development of Tsinghua University’s School of Clinical Medicine in the field of peritoneal cancer prevention and treatment, and it also lays an even more solid foundation for the establishment of a national framework of clinical practice guidelines for the diagnosis and management of peritoneal malignancies.